Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma

被引：1
|
作者：
Inyang, Eno [1 ]
Aktas-Samur, Anil [2 ]
Munshi, Nikhil C. [3 ]
Leblebjian, Hour [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Pharm, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146605
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
666
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy
    Voorhees, Peter M.
    Laubach, Jacob
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2013, 121 (05) : 858 - 858
  • [2] Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy
    Odikadze, Levani
    Joseph, Nisha
    Schmidt, Timothy M.
    Heffner, Leonard
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Gupta, Vikas A.
    Boise, Lawrence H.
    Jaye, David L.
    Lonial, Sagar
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    BLOOD, 2018, 132
  • [3] Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
    Harvey, R. Donald
    Kaufman, Jonathan L.
    Heffner, Leonard T.
    Hofmeister, Craig C.
    Dhodapkar, Mahdav V.
    Lonial, Sagar
    Nooka, Ajay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)
    Inyang, Eno
    Munshi, Nikhil C.
    Aktas-Samur, Anil
    Leblebjian, Houry
    BLOOD, 2020, 136
  • [5] Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Piedra, Katrina
    Peterson, Tim
    Tan, Carlyn
    Orozco, Jennifer
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Lesokhin, Alexander
    Shah, Urvi
    Lu, Sydney
    Patel, Dhwani
    Derkach, Andriy
    Wilkins, Cy R.
    Korde, Neha
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) : 105 - 109
  • [6] Our Experience of Using Lenalidomide, Bortezomib and Dexamethasone (RVD) Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Pogosyan, Gayane
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S340 - S341
  • [7] Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
    Joseph, Nisha
    Almaula, Dhwani
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Nooka, Ajay
    BLOOD, 2017, 130
  • [8] Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients
    Joseph, Nisha
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Dhodapkar, Madhav V.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2018, 132
  • [9] Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Kukreti, Vishal
    BLOOD, 2011, 118 (21) : 1266 - 1267
  • [10] Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
    A K Nooka
    J L Kaufman
    S Muppidi
    A Langston
    L T Heffner
    C Gleason
    D Casbourne
    D Saxe
    L H Boise
    S Lonial
    Leukemia, 2014, 28 : 690 - 693
12345